chr7-127593918-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_020369.3(FSCN3):c.65G>A(p.Ser22Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000058 in 1,604,818 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_020369.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FSCN3 | NM_020369.3 | c.65G>A | p.Ser22Asn | missense_variant | 1/7 | ENST00000265825.6 | NP_065102.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FSCN3 | ENST00000265825.6 | c.65G>A | p.Ser22Asn | missense_variant | 1/7 | 1 | NM_020369.3 | ENSP00000265825 | P1 | |
FSCN3 | ENST00000478328.1 | n.544-1389G>A | intron_variant, non_coding_transcript_variant | 1 | ||||||
FSCN3 | ENST00000478821.1 | c.-259+166G>A | intron_variant | 5 | ENSP00000473531 | |||||
FSCN3 | ENST00000421705.1 | c.65G>A | p.Ser22Asn | missense_variant, NMD_transcript_variant | 1/4 | 3 | ENSP00000402472 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152226Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000171 AC: 4AN: 233984Hom.: 0 AF XY: 0.00000793 AC XY: 1AN XY: 126066
GnomAD4 exome AF: 0.0000626 AC: 91AN: 1452592Hom.: 0 Cov.: 31 AF XY: 0.0000444 AC XY: 32AN XY: 721280
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152226Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74362
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 30, 2024 | The c.65G>A (p.S22N) alteration is located in exon 1 (coding exon 1) of the FSCN3 gene. This alteration results from a G to A substitution at nucleotide position 65, causing the serine (S) at amino acid position 22 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at